← FDA DRUG APPROVALS

FDA ANDA · ANDA060716

POLYMYXIN B

polymyxin b sulfate

Sponsor: HIKMA

APPLICATION
ANDA060716
TYPE
ANDA
ORIGINAL APPROVAL
1964-06-29
LATEST ACTION
2025-07-03
ROUTE
INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS, OPHTHALMIC, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

POLYMYXIN B SULFATEDiscontinued
POLYMYXIN B SULFATE EQ 500,000 UNITS BASE/VIAL · INJECTABLE · INJECTION

Approval history

2025-07-03Labeling · Supplement 27 · standardAP
2019-03-29Manufacturing (CMC) · Supplement 26AP
2012-01-30Labeling · Supplement 20LabelAP
2012-01-27Labeling · Supplement 18LabelAP
2002-05-15Manufacturing (CMC) · Supplement 15AP
2000-11-28Manufacturing (CMC) · Supplement 14AP
2000-11-28Manufacturing (CMC) · Supplement 12AP
2000-11-28Manufacturing (CMC) · Supplement 13AP
1996-08-26Manufacturing (CMC) · Supplement 9AP
1996-08-26Manufacturing (CMC) · Supplement 8AP
1996-08-26Labeling · Supplement 10AP
1996-05-31Manufacturing (CMC) · Supplement 11AP
1992-04-17Manufacturing (CMC) · Supplement 7AP
1989-08-03Manufacturing (CMC) · Supplement 6AP
1964-06-29OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →